786-OHomo sapiens (Human)Cancer cell line
Also known as: 786-o, 786O, 786-0, 786.O, 786-O RCC, RCC 786-O, RCC_7860, RCC 7860, 7860, 786-0WT, 796-0 (Occasionally.), 768-0 (Occasionally.)
Quick Overview
Human renal cell carcinoma cell line with clear cell morphology and VHL mutations.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1051 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Kidney[UBERON:UBERON_0002113] |
Donor Information
| Age | 58 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Renal cell carcinoma |
|---|---|
| Lineage | Kidney |
| Subtype | Renal Clear Cell Carcinoma |
| OncoTree Code | CCRCC |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000649_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | PTEN | p.Gln149Ter (c.445C>T) | Homozygous | - | from parent cell line 786-O |
| MutationSimple | TERT | c.1-124C>T (c.228C>T) (C228T) | Unspecified | In promoter | from parent cell line Hep-G2 |
| MutationSimple | TP53 | c.560-2A>G | Homozygous | Splice acceptor mutation | PubMed=29970484 |
| MutationSimple | TP53 | p.Pro278Ala (c.832C>G) | Unspecified | - | PubMed=18006756, PubMed=12884349 |
| MutationSimple | VHL | p.Gly104Alafs*55 (c.311delG) | Unspecified | - | PubMed=7915601 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2alpha as molecular triggers?
Nogueira I., Dias F., Morais M., Teixeira A.L., Medeiros R.
Future Oncol. 15:2361-2370(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Metabolic footprinting of a clear cell renal cell carcinoma in vitro model for human kidney cancer detection.
Monge M.E.
J. Proteome Res. 17:3877-3888(2018).
Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.
Hsieh J.J.-D., Hakimi A.A.
Nat. Commun. 8:15165.1-15165.10(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Choosing the right cell line for renal cell cancer research.";
Czarnecka A.M.
Mol. Cancer 15:83.1-83.15(2016).
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
Mob. DNA 7:20.1-20.11(2016).
In vitro cultivation of human renal cell cancer. II. Characterization of cell lines.
Williams R.D., Elliott A.Y., Stein N., Fraley E.E.
In Vitro 14:779-786(1978).
In vitro cultivation of human renal cell cancer. I. Establishment of cells in culture.
Williams R.D., Elliott A.Y., Stein N., Fraley E.E.
In Vitro 12:623-627(1976).
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
J. Natl. Cancer Inst. 83:757-766(1991).
Mutations of the VHL tumour suppressor gene in renal carcinoma.";
Linehan W.M.
Nat. Genet. 7:85-90(1994).
Systematic variation in gene expression patterns in human cancer cell lines.
Botstein D., Brown P.O.
Nat. Genet. 24:227-235(2000).
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Otterud B.E., Leppert M.F., Storb R., Sandmaier B.M.
Clin. Cancer Res. 10:7799-7811(2004).
HLA class I and II genotype of the NCI-60 cell lines.";
Morse H.C. 3rd, Stroncek D., Marincola F.M.
J. Transl. Med. 3:11.1-11.8(2005).
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mol. Cancer Ther. 5:2606-2612(2006).
DNA fingerprinting of the NCI-60 cell line panel.";
Chanock S.J., Weinstein J.N.
Mol. Cancer Ther. 8:713-724(2009).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Ambudkar S.V., Gottesman M.M.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma.
Mimata H., Seto M., Moriyama M.
BMC Cancer 11:523.1-523.10(2011).
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
PLoS ONE 7:E31628-E31628(2012).
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
Yoon C.N., Chang Y.-T.
PLoS ONE 7:E32096-E32096(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Science 336:1040-1044(2012).
Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Pawlowski R., Muhl S.M., Sulser T., Krek W., Moch H., Schraml P.
Int. J. Cancer 132:E11-E17(2013).
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
Cancer Res. 73:4372-4382(2013).
Global proteome analysis of the NCI-60 cell line panel.";
Wilhelm M., Kuster B.
Cell Rep. 4:609-620(2013).
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Hirshfield K.M., Oltvai Z.N., Vazquez A.
Cancer Metab. 1:20.1-20.13(2013).
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
PLoS ONE 9:E92047-E92047(2014).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A mass spectrometric-derived cell surface protein atlas.";
Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
PLoS ONE 10:E0121314-E0121314(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
J. Proteomics 139:77-83(2016).
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data Brief 7:1302-1305(2016).